Whan In PharmLtd Balance Sheet Health
Financial Health criteria checks 6/6
Whan In PharmLtd has a total shareholder equity of ₩374.2B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩422.9B and ₩48.8B respectively. Whan In PharmLtd's EBIT is ₩27.0B making its interest coverage ratio -8.2. It has cash and short-term investments of ₩51.5B.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | -8.2x |
| Cash | ₩51.53b |
| Equity | ₩374.16b |
| Total liabilities | ₩48.78b |
| Total assets | ₩422.94b |
Recent financial health updates
No updates
Recent updates
Did Whan In Pharm Co.,Ltd. (KRX:016580) Use Debt To Deliver Its ROE Of 7.8%?
Mar 15
Here's Why I Think Whan In PharmLtd (KRX:016580) Might Deserve Your Attention Today
Feb 25Whan In Pharm Co.,Ltd.'s (KRX:016580) 1.6% Dividend Yield Looks Pretty Interesting
Feb 04
What Is The Ownership Structure Like For Whan In Pharm Co.,Ltd. (KRX:016580)?
Jan 14Why You Might Be Interested In Whan In Pharm Co.,Ltd. (KRX:016580) For Its Upcoming Dividend
Dec 24Does Whan In Pharm Co.,Ltd. (KRX:016580) Create Value For Shareholders?
Dec 11Whan In PharmLtd's (KRX:016580) Shareholders Are Down 33% On Their Shares
Nov 20Financial Position Analysis
Short Term Liabilities: A016580's short term assets (₩199.0B) exceed its short term liabilities (₩43.8B).
Long Term Liabilities: A016580's short term assets (₩199.0B) exceed its long term liabilities (₩4.9B).
Debt to Equity History and Analysis
Debt Level: A016580 is debt free.
Reducing Debt: A016580 has not had any debt for past 5 years.
Debt Coverage: A016580 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A016580 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Whan In Pharm Co.,Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Hanwha Investment & Securities Co., Ltd. |
| Jonathan Rhee | Hyundai Motor Securities Co. Ltd. |
| Seung-Ho Lee | iM Securities |